# Safety, Tolerability and Immunogenicity of an Inactivated Whole-cell Pneumococcal Vaccine Gamma-PN3.

> **NCT05667740** · PHASE1 · COMPLETED · sponsor: **GPN Vaccines** · enrollment: 118 (actual)

## Conditions studied

- Pneumococcal Infections

## Interventions

- **BIOLOGICAL:** Gamma-PN3
- **BIOLOGICAL:** Prevenar-13
- **BIOLOGICAL:** Pneumovax-23
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05667740
- **Lead sponsor:** GPN Vaccines
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-16
- **Primary completion:** 2023-10-08
- **Final completion:** 2023-10-08
- **Target enrollment:** 118 (ACTUAL)
- **Last updated:** 2024-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05667740

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05667740, "Safety, Tolerability and Immunogenicity of an Inactivated Whole-cell Pneumococcal Vaccine Gamma-PN3.". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05667740. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*